23
Apr

Edinburgh, UK, 23rd April 2018 / Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK.

15
Mar
ASGCT banner

As product developers move toward 2nd generation gene and cell medicine constructs, the importance of novel gene regulation and promoter elements has emerged. Synpromics is pleased to invite you to join them for a special symposium during the ASGCT Annual Meeting which will include presentations from Synpromics’ partners, an interactive panel discussion, and will be followed by a networking reception and refreshments. Please see the full agenda below.

12
Mar
BioCentury Innovations

Bringing synthetic biology to transcriptional regulation could catalyse a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. In a recent article for BioCentury Innovations, Karen Tkach Tuzman spoke to Dr Michael Roberts, CSO of Synpromics, about synthetic promoters and how Synpromics is using combinations of natural gene sequences to guide gene expression. 

23
Feb
medical expo e magazine

Artificial Intelligence is a hot topic of conversation in pretty much every industry all the way from manufacturing to education. Biotech is no exception and given the sheer amount of genomic data being produced AI is becoming an integral part of gene therapy research. This could lead to greater precision in gene editing and ultimately more personalised treatments in the future. Dr Michael Roberts, CSO of Synpromics, spoke to Daniel Allen about the role AI can play in genomic medicine and the ways Synpromics is already utilising it.

26
Jan
MedNous

The past decade has seen a resurgence in the field of cell and gene therapy, with three treatments being approved by the European Medicines Agency and the US Food and Drug Administration and a flood of candidate therapies nearing the end of Phase 3 clinical trials, a number of which are demonstrating promising results.

Read the full article published by MedNous – download PDF.

Pages